1.92
1.54%
-0.03
After Hours:
1.9001
-0.0199
-1.04%
Emergent Biosolutions Inc stock is currently priced at $1.92, with a 24-hour trading volume of 865.63K.
It has seen a -1.54% decreased in the last 24 hours and a -21.31% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.01 pivot point. If it approaches the $1.89 support level, significant changes may occur.
Previous Close:
$1.95
Open:
$2.01
24h Volume:
865.63K
Market Cap:
$100.59M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.1589
EPS:
-12.08
Net Cash Flow:
$-257.90M
1W Performance:
-5.88%
1M Performance:
-21.31%
6M Performance:
-10.70%
1Y Performance:
-78.64%
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
400 Professional Drive, Gaithersburg, MD
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
May-05-21 | Downgrade | Argus | Buy → Hold |
Apr-07-21 | Initiated | The Benchmark Company | Buy |
Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-14-20 | Resumed | JP Morgan | Neutral |
Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
Sep-12-19 | Initiated | Guggenheim | Buy |
Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
Jun-13-18 | Initiated | Argus | Buy |
Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
Jan-24-18 | Initiated | Goldman | Neutral |
Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
Jun-28-16 | Reiterated | Singular Research | Buy |
Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
Mar-28-16 | Initiated | Singular Research | Buy |
Feb-19-16 | Initiated | Wells Fargo | Outperform |
May-15-14 | Initiated | Summer Street Research | Buy |
May-31-11 | Reiterated | WBB Securities | Strong Buy |
Jan-10-11 | Reiterated | Wedbush | Outperform |
Nov-05-10 | Reiterated | Wedbush | Outperform |
Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GlobeNewswire Inc.
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
GlobeNewswire Inc.
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GlobeNewswire Inc.
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales
Zacks Investment Research
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Benzinga
Emergent Biosolutions Inc Stock (EBS) Financials Data
Emergent Biosolutions Inc (EBS) Revenue 2024
EBS reported a revenue (TTM) of $1.02 billion for the quarter ending December 31, 2023, a -5.11% decline year-over-year.
Emergent Biosolutions Inc (EBS) Net Income 2024
EBS net income (TTM) was -$757.20 million for the quarter ending December 31, 2023, a -253.50% decrease year-over-year.
Emergent Biosolutions Inc (EBS) Cash Flow 2024
EBS recorded a free cash flow (TTM) of -$257.90 million for the quarter ending December 31, 2023, a -72.05% decrease year-over-year.
Emergent Biosolutions Inc (EBS) Earnings per Share 2024
EBS earnings per share (TTM) was -$14.76 for the quarter ending December 31, 2023, a -213.38% decline year-over-year.
About Emergent Biosolutions Inc
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Cap:
|
Volume (24h):